ERα Gene Promoter Methylation in Cognitive Function and Quality of Life of Patients With Alzheimer Disease

Li, Kai-Xiu; Sun, Qi; Wei, Lingling; Du, Guizhi; Xue, Huang; Wang, Jun-Kang

doi:10.1177/0891988719835325

Cited by 12 publications

(10 citation statements)

References 38 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data validate that estrogen conducts anti-inflammatory action via ERα in microglia [150]. Moreover, patients with higher ERα promoter methylation rates showed decreased ERα mRNA expression and impaired cognition [151], which implies the importance of ERα in AD. As mentioned, it is becoming more and more appreciated that infection may be one causative factor for AD.…”

Section: The Role Of Estrogen In Adsupporting

confidence: 66%

From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy

Cheng

Lin

Lane

2021

IJMS

View full text Add to dashboard Cite

The impacts of menopause on neurodegenerative diseases, especially the changes in steroid hormones, have been well described in cell models, animal models, and humans. However, the therapeutic effects of hormone replacement therapy on postmenopausal women with neurodegenerative diseases remain controversial. The steroid hormones, steroid hormone receptors, and downstream signal pathways in the brain change with aging and contribute to disease progression. Estrogen and progesterone are two steroid hormones which decline in circulation and the brain during menopause. Insulin-like growth factor 1 (IGF-1), which plays an import role in neuroprotection, is rapidly decreased in serum after menopause. Here, we summarize the actions of estrogen, progesterone, and IGF-1 and their signaling pathways in the brain. Since the incidence of Alzheimer’s disease (AD) is higher in women than in men, the associations of steroid hormone changes and AD are emphasized. The signaling pathways and cellular mechanisms for how steroid hormones and IGF-1 provide neuroprotection are also addressed. Finally, the molecular mechanisms of potential estrogen modulation on N-methyl-d-aspartic acid receptors (NMDARs) are also addressed. We provide the viewpoint of why hormone therapy has inconclusive results based on signaling pathways considering their complex response to aging and hormone treatments. Nonetheless, while diagnosable AD may not be treatable by hormone therapy, its preceding stage of mild cognitive impairment may very well be treatable by hormone therapy.

show abstract

Section: The Role Of Estrogen In Adsupporting

confidence: 66%

From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy

Cheng

Lin

Lane

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The QOL of the participants was tested with the QOL- AD scale and their cognitive abilities were assessed using both the Mini-Mental State Examination (MMSE) and the activities of daily living (ADL) tests. The methylation status and level of expression of the ERα gene were determined in the peripheral blood of 132 patients with AD and 135 healthy control subjects ( Li et al, 2019 ). This study showed that a higher level of methylation of the ERα gene promoter correlated with a decreased ERα expression and reduced cognitive abilities in AD patients ( Li et al, 2019 ).…”

Section: Estrogenic Plants and Compounds With Potential Effects Against Alzheimer's Diseasementioning

confidence: 99%

“…The methylation status and level of expression of the ERα gene were determined in the peripheral blood of 132 patients with AD and 135 healthy control subjects ( Li et al, 2019 ). This study showed that a higher level of methylation of the ERα gene promoter correlated with a decreased ERα expression and reduced cognitive abilities in AD patients ( Li et al, 2019 ). This evidence supports the view that lower estrogenic signaling correlates with cognitive impairment in AD.…”

Section: Estrogenic Plants and Compounds With Potential Effects Against Alzheimer's Diseasementioning

confidence: 99%

Estrogenic Plants: to Prevent Neurodegeneration and Memory Loss and Other Symptoms in Women After Menopause

et al. 2021

View full text Add to dashboard Cite

In mammals, sexual hormones such as estrogens play an essential role in maintaining brain homeostasis and function. Estrogen deficit in the brain induces many undesirable symptoms such as learning and memory impairment, sleep and mood disorders, hot flushes, and fatigue. These symptoms are frequent in women who reached menopausal age or have had ovariectomy and in men and women subjected to anti-estrogen therapy. Hormone replacement therapy alleviates menopause symptoms; however, it can increase cardiovascular and cancer diseases. In the search for therapeutic alternatives, medicinal plants and specific synthetic and natural molecules with estrogenic effects have attracted widespread attention between the public and the scientific community. Various plants have been used for centuries to alleviate menstrual and menopause symptoms, such as Cranberry, Ginger, Hops, Milk Thistle, Red clover, Salvia officinalis, Soy, Black cohosh, Turnera diffusa, Ushuva, and Vitex. This review aims to highlight current evidence about estrogenic medicinal plants and their pharmacological effects on cognitive deficits induced by estrogen deficiency during menopause and aging.

show abstract

“…Cognitive impairment is a pronounced symptom of AD, and it gets worse as the disease progresses . MMSE is a neuropsychological examination consisting of a series of questions and cognitive tests that are commonly used to assess the cognitive impairment and degree of dementia . In our study, we evaluated the correlations of miR‐103 and miR‐107 with MMSE score in AD patients and observed that both miR‐103 and miR‐107 were positively correlated with MMSE score and negatively associated with dementia severity in AD patients, which indicated that miR‐103 and miR‐107 might attenuate the disease progression of AD.…”

Section: Discussionmentioning

confidence: 79%

An investigation of microRNA‐103 and microRNA‐107 as potential blood‐based biomarkers for disease risk and progression of Alzheimer's disease

Wang

Chen

Zhang

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background: This study aimed to assess the correlation of circulating microRNA-103 (miR-103) and microRNA-107 (miR-107) with disease risk and cognitive impairment of Alzheimer's disease (AD).Methods: Plasma samples from 120 AD patients, 120 Parkinson's disease (PD) patients (served as disease control), and 120 healthy controls were collected for miR-103 and miR-107 detections using real-time quantitative polymerase chain reaction. Mini-Mental State Examination (MMSE) score was documented and was used to accordingly assess the dementia severity.Results: miR-103 expression was decreased in AD patients compared with PD patients and healthy controls, and receiver operating characteristic (ROC) curve analyses illustrated that it was able to differentiate AD patients from PD patients and healthy controls. Additionally, miR-103 positively correlated with MMSE score and negatively correlated with dementia severity in AD patients. miR-107 expression was lower in AD patients compared with healthy controls but similar between AD patients and PD patients, and ROC curve analyses revealed that it was able to differentiate AD patients from healthy controls but not AD patients from PD patients. miR-107 was positively correlated with MMSE score and negatively correlated with dementia severity in AD patients, while the correlation coefficient of miR-107 with MMSE score was lower than that of miR-103 with MMSE score. Besides, miR-103 was positively correlated with miR-107 in AD patients, PD patients, and healthy controls.

show abstract

ERα Gene Promoter Methylation in Cognitive Function and Quality of Life of Patients With Alzheimer Disease

Cited by 12 publications

References 38 publications

From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy

From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy

Estrogenic Plants: to Prevent Neurodegeneration and Memory Loss and Other Symptoms in Women After Menopause

An investigation of microRNA‐103 and microRNA‐107 as potential blood‐based biomarkers for disease risk and progression of Alzheimer's disease

Contact Info

Product

Resources

About